Gentherm Stock Down 60% Since 2022 — But One Hedge Fund Just Bought 431,072 Shares

New York-based Harvey Partners increased its Gentherm (NASDAQ: THRM) stake by 431,072 shares in Q3, raising the position by about $18.1 million to roughly 1.0 million shares valued at $34.9 million (3.1% of reportable U.S. equity AUM). Gentherm reported record Q3 revenue of $386.9 million (+4% YoY), adjusted EBITDA of $49 million (12.7% margin), and YTD operating cash flow of $87.8 million (vs. $73.1M prior year), while securing $745 million in new automotive awards and remaining on pace for >$2 billion in awards this year. The stock trades at $36.46, down ~13% over the past year, and Harvey’s purchase signals institutional interest amid improving operational metrics despite prior multi-year underperformance.

Analysis

Market structure: Harvey Partners’ size-up in THRM (now ~$35m position, 3.1% of reported U.S. equity AUM) signals investor conviction that Gentherm is winning share in thermal systems—$745m in new automotive awards and record Q revenue ($386.9m) point to demand growth from EV battery thermal and cabin comfort niches. Winners include Gentherm and specialized EV thermal subsystem suppliers; losers are undifferentiated, commodity-exposed tier‑2 parts makers facing margin compression. Cross-asset: stronger award cadence reduces idiosyncratic credit risk but keeps cyclicality high—auto cyclics could widen credit spreads on OEM weakness; copper/aluminum moves matter for gross margins, FX (EUR/USD) affects European OEM margins.

Risk assessment: Tail risks include sudden OEM production cuts, loss of a major OEM contract, or an adverse FDA action on medical products which could knock 10–25% of revenue off historically concentrated client books; raw-material inflation remains a persistent margin tail risk. Immediate (days) impact from the 13F is negligible; short-term (weeks/months) catalysts are upcoming earnings, award conversion and backlogs; long-term (2–5 years) is structural EV adoption—THRM’s revenue leverage to EV penetration is the primary upside.

Trade implications: Direct play = selective long THRM sized to firm view on award conversion; use 6–12 month call spreads to cap downside while keeping upside. Pair trade = long THRM vs short market beta (SPY) to isolate company-specific recovery over 6–12 months. Rotate 1–3% from broad, commodity‑sensitive auto suppliers into differentiated tech-exposed names (THRM, AZZ, BWXT) and use cash-secured puts to buy dips beneath $30.

Contrarian angles: Consensus discounts secular EV tailwinds given 13% YTD underperformance vs S&P; that may underprice order-book growth but overstates margin recovery—$2bn+ award guidance is pipeline, not revenue. Historical parallels (supplier cycles like Lear, Visteon) show revenue turnarounds can precede margin normalization by 2–4 quarters; unintended risks include OEM insourcing of thermal tech or rapid battery chemistry shifts that commoditize Gentherm’s IP.

Key Decisions for Investors

• Establish a 2–3% long position in THRM (ticker THRM) at market (~$36.5) with an initial stop-loss at 18% (sell if < $30) and plan to scale to 4–5% if two consecutive quarters show Y/Y revenue growth and operating cash flow increases (e.g., YTD OCF > $120M) or if awarded backlog converts toward >$2bn guidance within 6 months.
• Implement a defined-risk options trade: buy a 6–12 month call spread (e.g., Jan 2026 35C / 50C) sizing at 0.5–1.0% of portfolio to capture upside while capping premium loss; alternatively sell cash-secured 6-month 30P if implied volatility yields >=4% premium and you are willing to own THRM at $30.
• Run a dollar‑neutral pair: long THRM and short SPY sized to neutralize market beta (~0.9x THRM exposure) for a 6–12 month horizon to isolate company-specific re‑rating; trim if THRM fails to hold $30 or if SPY rallies >6% while THRM lags by >15% in 30 days.
• Reallocate 1–3% from broad, commodity‑exposed auto supplier holdings into differentiated names: add to THRM and selectively to AZZ and BWXT (tickers THRM, AZZ, BWXT). Monitor two specific 30–90 day indicators before adding: (1) quarterly award-to-revenue conversion rate (target: >10% quarterly conversion), (2) sequential improvement in adjusted EBITDA margin (target: +100–200bps q/q).